Russell Beth, Moss Charlotte, Rigg Anne, Van Hemelrijck Mieke
Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London SE1 9RT, UK.
Denotes joint first authorship.
Ecancermedicalscience. 2020 Mar 30;14:1023. doi: 10.3332/ecancer.2020.1023. eCollection 2020.
Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. Therefore, this review aimed to collate information available in published articles to identify any evidence behind these claims with the aim of advising clinicians on how best to treat patients. This review found no published evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection, however, conflicting evidence from the World Health Organisation surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients.
鉴于当前的新型冠状病毒（COVID-19）大流行，为临床医生和患者提供可靠信息至关重要。有许多报告称，非甾体抗炎药（NSAIDs）和皮质类固醇可能会加重COVID-19患者的症状。因此，本综述旨在整理已发表文章中的可用信息，以确定这些说法背后的任何证据，旨在为临床医生提供有关如何最佳治疗患者的建议。本综述未发现支持或反对在COVID-19患者中使用非甾体抗炎药的已发表证据。同时，似乎有一些证据表明，如果在感染的早期急性期使用皮质类固醇可能有益，然而，世界卫生组织关于在某些病毒感染中使用皮质类固醇的相互矛盾的证据意味着这一证据并不确凿。鉴于目前的文献情况，在有更多关于COVID-19患者使用非甾体抗炎药和皮质类固醇的证据出现之前，应谨慎行事。
